Many Americans—lawmakers and patients alike—are demanding more clarity around why prescription drugs cost so much and who profits along the way. In response, states across the country have been quietly but steadily passing drug price transparency laws designed to hold manufacturers, insurers, and pharmacy benefit managers (PBMs) more accountable. Here's what's new in 2026.
What's Changed in State Drug Transparency Laws for 2026?
The most notable shift this year is the tightening of price increase reporting thresholds. States that already required manufacturers to disclose price hikes have lowered the bar for what triggers a report, meaning more increases must now be disclosed. Connecticut and Virginia have gone a step further, requiring manufacturers to proactively report pricing information on costly new drugs entering the market.
Another major development: more than 20 states now mandate disclosure of the rebates manufacturers pay to pharmacy benefit managers. These rebates have long been a black box in the drug pricing system. By requiring their disclosure, states hope to get a clearer picture of what medications actually cost at the net level—and whether those savings are being passed on to patients.
The federal 340B Drug Pricing Program—which requires manufacturers to sell outpatient drugs at discounted rates to qualifying healthcare providers serving low-income patients—is also under increased scrutiny. States like Indiana and Idaho are enacting measures to verify that those discounts are actually reaching safety-net providers rather than being absorbed elsewhere in the supply chain.
Meanwhile, New York, New Mexico, and New Jersey are all pushing for finer-grained data and broader disclosure requirements. Here's a closer look at each.
California
California Code of Regulations Title 22, Section 96082 now includes a formal appeals process for manufacturers who receive a penalty notice for failing to report a required price increase. While this may seem like a procedural detail, it reflects the state's broader commitment to enforcing its transparency rules consistently.
Louisiana
Louisiana requires drug manufacturers to notify the state's insurance commissioner whenever a drug with a wholesale acquisition cost (WAC) of $100 or more for a 30-day supply has seen a price increase of at least 50%. These notifications must be submitted in writing via email, creating a documented record of significant price jumps.
New York
New York manufacturers must file notice within 60 days whenever a prescription drug with a WAC of at least $40 per treatment course increases in price by more than 16% over any 24-month period.
Separately, New York now requires all PBMs operating in the state to register and disclose financial and operational information. This is a significant step toward illuminating how PBMs generate revenue and whether their practices benefit—or work against—patients.
New Mexico
New Mexico's Prescription Drug Price Transparency Act casts a wide net, requiring reporting from drug manufacturers, health insurers, PBMs, and pharmacy services administrative organizations.
Manufacturers must report on:
- Brand-name drugs with a WAC of $400 or more for a monthly supply
- Drugs that experience significant price increases
- New drugs with a WAC exceeding the Medicare Part D specialty tier threshold
New Jersey
In New Jersey, manufacturers must notify the Division of Consumer Affairs when a brand-name drug's WAC increases by 10% or more within a 12-month window, or when a new drug launches with a WAC of $670 or more per unit.
New Jersey has also taken direct aim at spread pricing—a practice where PBMs profit from the gap between what they charge health insurers and what they actually reimburse pharmacies. That practice is now prohibited in the state.
What This Means for Patients
These laws are a step in the right direction, but transparency alone doesn't make medications affordable. Even with better price reporting, millions of uninsured and underinsured Americans still face retail drug costs that are simply out of reach. That's where a prescription assistance program can make a real difference.
ClariMeds is a full-service medication assistance program that helps patients access free brand-name medications through manufacturer patient assistance programs. We research every available source of brand name drug financial assistance, handle the paperwork, and manage ongoing enrollment—so you're not left navigating a confusing system on your own.
Whether you're looking for prescription help as an uninsured patient or simply need help paying for prescriptions that your current coverage doesn't fully cover, ClariMeds can connect you with the right manufacturer assistance program for your situation.
If you're struggling with the cost of your medications, start here and let ClariMeds do the work of finding and maintaining your enrollment in every assistance program you qualify for.
Frequently Asked Questions
What Are Pharmacy Benefit Managers?
Pharmacy benefit managers are companies that administer prescription drug benefits on behalf of employers, health insurers, and government programs. They negotiate prices with drug manufacturers, design drug formularies, and process pharmacy claims.
The challenge is that PBMs have historically kept manufacturer rebates confidential, making it nearly impossible to know whether those negotiated savings ever reach the patient at the pharmacy counter—or whether they're retained as profit by the PBM.
Are There Federal Drug Price Transparency Laws?
Yes. At the federal level, the Transparency in Coverage rules require health plans to disclose pricing data, and the Medicare Drug Price Negotiation Program allows the federal government to directly negotiate prices on certain high-cost drugs. A proposed measure—the Drug-Price Transparency for Consumers Act—would require drug pricing information to appear in direct-to-consumer advertisements, though it has not yet been passed into law.
Are Drug Prices Regulated in the United States?
For the most part, no. Unlike many other countries, the U.S. does not have a centralized system for setting or capping drug prices. Manufacturers, distributors, and retailers largely set prices on their own, which is a key reason why the same medication can cost dramatically more in the U.S. than in other developed nations—and why programs offering free brand name medication or prescription assistance can be so valuable for patients who can't afford retail prices.